Somatostatin receptor based hybrid imaging in sarcoidosis
- PMID: 29782604
- PMCID: PMC5954781
- DOI: 10.1186/s41824-017-0014-y
Somatostatin receptor based hybrid imaging in sarcoidosis
Abstract
Several diagnostic imaging methodologies are available for the clinical evaluation of sarcoidosis, but all have their limitations. FDG PET/CT is frequently used, but this technique does not provide optimal results in all cases. Novel radiopharmaceuticals aimed at other disease targets may be helpful, particularly in cardiac sarcoidosis when FDG PET/CT has a low diagnostic accuracy, due to difficulties in preparing the patients who should use a specific diet combined with prolonged fasting. 68Ga-labeled somatostatin based receptor hybrid imaging is a potential alternative to FDG PET/CT. This short communication provides a rapid overview of initial findings concerning the application of 68Ga-labeled somatostatin based receptor hybrid imaging in the diagnosis of (cardiac) sarcoidosis activity.
Keywords: Cardiac; PET/CT; Sarcoidosis; Somatostatin receptor imaging.
Conflict of interest statement
Informed consent was not required (since this is a retrospective study).The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures

References
-
- Hanneman K, Kadoch M, Guo HH, Jamali M, Quon A, Iagaru A et al. Initial Experience With Simultaneous 18F-FDG PET/MRI in the Evaluation of Cardiac Sarcoidosis and Myocarditis. Clin Nucl Med 2017;42(7):e328–e334 - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources